Eli Lilly and Company (lly)
LLY — Company Overview
Investors tracking LLY follow a Drug Manufacturers - General name listed on NYQ within Healthcare.
| Ticker | LLY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $1.06T |
| Last price | $1,191.94 |
| Size category | Mega Cap |
LLY — Business Description
The business profile of Eli Lilly and Company (LLY) reflects its role in Drug Manufacturers - General. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and h…
Official website: https://www.lilly.com.
LLY — Investment Thesis
Eli Lilly and Company (LLY) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 47.7% year-over-year (public data).
- Trailing P/E of 39.22× implies elevated growth expectations at the current price.
- Forward P/E (25.81×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 0.6% adds an income component to total return.
- Equity market capitalization is approximately $1.06T.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
LLY — Financial Health
LLY financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin of 33.5% indicates solid bottom-line conversion. Debt-to-equity of 139.01 warrants monitoring in a higher-rate environment.
| Trailing P/E | 39.22× |
| Forward P/E | 25.81× |
| Price / Sales | 13.34× |
| Price / Book | 34.14× |
| Gross margin | 83.4% |
| Operating margin | 54.2% |
| Profit margin | 33.5% |
| Debt / Equity | 139.01 |
LLY — Growth Outlook
Growth outlook for Eli Lilly and Company (LLY) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 47.7% indicates strong top-line momentum.
- Earnings growth of 26.2% year-over-year supports improving profitability.
- Price is 4.6% below the 52-week high.
LLY — Competitive Position
Eli Lilly and Company (LLY) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $1.06T places LLY among mega-cap peers.
- Gross margin near 83.4% may reflect pricing power or favorable mix.
LLY — Strengths
Strengths for Eli Lilly and Company (LLY) inferred from public financial metrics:
- Revenue growth of 47.7% year-over-year.
- Earnings growth of 26.2% year-over-year.
- Gross margin of 83.4% supports competitive unit economics.
- Mega Cap scale ($1.06T) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
LLY — Weaknesses
Weaknesses and pressure points for Eli Lilly and Company (LLY) based on available data:
- Elevated trailing P/E (39.22×) limits valuation margin of safety.
LLY — Opportunities
- Sustained revenue growth (47.7%) could support multiple expansion if margins hold.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
LLY — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
LLY — Summary
Eli Lilly and Company (LLY) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $1191.94 with market cap $1.06T. Trailing P/E 39.22×. Revenue grew 47.7% year-over-year per public data. Notable strengths include revenue growth of 47.7% year-over-year. Key watch items include elevated trailing p/e (39.22×) limits valuation margin of safety. For analyst estimates, ownership, and live news on LLY, upgrade to Vest Terminal Professional.
Eli Lilly and Company FAQ
What does Eli Lilly and Company (LLY) do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100,…
What is LLY's P/E ratio?
Eli Lilly and Company has a trailing P/E of 39.22× based on publicly available market data.
Does LLY pay a dividend?
Indicated dividend yield: 0.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is LLY in?
Eli Lilly and Company is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is LLY's market capitalization?
Approximate market cap: $1.06T.
What are the main risks for LLY?
Key risks include elevated valuation, among factors on this page.
What are the strengths of LLY?
Potential positives include revenue growth of 47.7% year-over-year, earnings growth of 26.2% year-over-year.
Where can I get analyst estimates for LLY?
Consensus estimates, price targets, and detailed analyst data for Eli Lilly and Company are available to Professional subscribers in Vest Terminal — not on this public summary page.